The catalysts are:

     - Continued Ramp of Nuplazid and DayBue

     - Negative Symptoms of Schizophrenia Study

     - ACP-204 (son of Nuplazid)

 

 For me this stock will likely not be what I had wanted it to be by now.  It is disappointing.  My guess is that the stock is currently undervalued, but the only catalyst that would send this stock to the moon would be the results of phase II study of ACP-204 for Alzheimer's.  Since the study has not even started, this will likely take a couple of years.

 

I am waiting for my break-even at around $29 a share and then I plan on dumping a bunch of shares and holdind the rest long term.